血塞通注射液降低COPD患者肺动脉高压的作用及其机制  

Effect and Mechanism of Xueshuantong Injection on Alleviating Pulmonary Arterial Hypertension in COPD Patients

作　　者：唐兰兰[1,2] 吴成云[3] 王淑君[1] 黎关龙[1] 姚海霞[1,4] 王园园[1] 王万铁[1] 

机构地区：[1]温州医学院病理生理学系,浙江温州325035 [2]浙江中医药大学附属第二医院病理科,浙江杭州310005 [3]温州医学院附属第二医院呼吸内科,浙江温州325027 [4]温州医学院附属第一医院麻醉科,浙江温州325000

出　　处：《中华中医药学刊》2012年第9期2042-2045,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省中医药科技计划重点项目(2008ZA017)

摘　　要：目的:观察血塞通注射液降低COPD患者肺动脉高压的临床作用并探讨其可能机制。方法:将22例确诊慢性阻塞性肺疾病患者随机分为常规治疗组和血塞通治疗组,随机抽取11例无肺疾患正常人作为对照组。常规治疗组予支气管扩张剂、抗生素及吸入糖皮质激素,血塞通治疗组在常规治疗基础上加用血塞通针,正常对照组不予任何治疗措施,2周后比较3组肺功能、肺动脉压及血气分析,ELISA法检测血浆磷酸化Erk1/2、磷酸化P38MAPK蛋白表达情况,评价血塞通注射液对慢性阻塞性肺疾病肺动脉高压的影响及与MAPKs信号通路的关系。结果:(1)常规组和血塞通组治疗后肺动脉压、肺功能及血气分析各项指标均较治疗前明显改善,且血塞通组优于常规组(均P<0.05);(2)ELISA结果:血塞通组综合治疗后血浆p-ERK、p-P38表达降低(均P<0.01),常规组无明显差异(P>0.05),两组比较有统计学差异(均P<0.05)。结论:血塞通注射液可能通过抑制P38MAPK、ERK1/2通路,有效地降低COPD患者肺动脉压,改善肺功能。Objective ： To observe the effect of Xuesaitong injection on pulmonary hypertension in chronic obstructive pulmo- nary disease（COPD） patients and investigate its possible mechanism. Methods ：22 cases of patients with COPD were ran- domly divided into conventional treatment group （ group C ） and Xuesaitong treatment group （ group T）, 11 patients were randomly selected from healthy subjects without lung disease served as normal control group（ group N）. group C was giv- en standardizing normal drugs, and group T was added with Xueshuantong injection on the basis treatment above, group N was given no treatment. After 2 weeks,lung function, pulmonary arterial pressure and blood gas analysis were compared, and the protein expressions of phosphorylated Ei＇kl/2 and phospholylated P38MAPK in plasma were tested. Results ： （ 1 ） After treatment,in group T and group C pulmonary artery pressure, pulmonary function and blood gas analysis were obvi- ously improved （ P 〈 0.05 ） , and group T was better than group C （ P 〈 0.05 ）. （ 2 ） ELISA results ： in group T the expres- sions of p - ERK and p - P38 were decreased （ P 〈 0.01 ） , group C had no significant difference （ P 〉 0.05 ） , and there was a significant difference between the two groups（ P 〈 0.05 ）. Concluslon：Combination with Xuesaitong injection can ef- fectively reduce pulmonary artery pressure, improve lung function and blood gas analysis. （ 3 ） Xuesaitong may relieve HH- PH induced by COPD through inhibiting the activation of P38MAPK and ERK1/2 pathway.

关 键 词：血塞通注射液 低氧高二氧化碳 肺动脉高压 COPD MAPK 

分 类 号：R563[医药卫生—呼吸系统] R453.9[医药卫生—内科学]